Trial Profile
An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Tesidolumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 15 Jun 2023 Results assessing efficacy and safety of TESI and the effect of switching to IPTA monotherapy in PNH presented at the 28th Congress of the European Haematology Association
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 28 May 2022 This trial has been completed in Lithuania, according to European Clinical Trials Database record.